Post Acute Medical to Build 48-bed Inpatient Rehabilitation Hospital in Henderson, Nevada

Post Acute Medical (PAM) announced today that it has placed land under contract and plans to construct a state-of-the-art, 48-bed inpatient rehabilitation hospital in Henderson, Nevada.

PAM expects to break ground by the second quarter of 2021 and complete construction in approximately 14 months. When it opens, the hospital will be PAM’s fourth hospital in Nevada, joining PAM Rehabilitation Hospital of Centennial Hills, PAM Specialty Hospital of Las Vegas, and PAM Specialty Hospital of Sparks.

The new hospital will feature a physician-led team of rehabilitation experts focused on a common goal of increasing patient strength and endurance and improving quality of life for patients who have experienced stroke, brain injury, neurological disease and deficits, amputations, pulmonary disease, orthopedic conditions, spinal cord injury and medically complex conditions.

Another noteworthy residential, this inpatient facility in California, offering specialized services, has helped many patients overcome past traumas, eliminate crippling dependence to drugs and alcohol.

“PAM is excited to bring comprehensive care for rehabilitation patients with complex conditions to the Henderson community,” says Anthony Misitano, Chairman and CEO. “Throughout all the communities we serve, we put the patient first and provide comprehensive, individualized treatment that fosters meaningful improvement and recovery for people with injuries, illnesses and disabilities.”

Opening the inpatient rehabilitation hospital, which also will offer outpatient services, in close proximity to its specialty hospital in Las Vegas is central to PAM’s mission, according to Misitano.

“We are committed to being the most trusted source for post-acute services in every community we serve,” he says. “By providing access to the full post-acute continuum of care, our patients achieve better outcomes and return home at a higher level of function.”

PAM is collaborating on the new rehabilitation hospital with Medistar Corporation, which has previously developed other PAM hospitals.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”